Sound efficacy of prophylactic HPV vaccination
نویسندگان
چکیده
Prophylactic human papillomavirus vaccine efficacy is almost too good to be true. The benefits of herd immunity will, however, not be gained without high vaccine coverage. Here the authors of two recent papers on HPV16/18 vaccine efficacy elaborate on the basics and implications of this approach for infection and cancer prevention.
منابع مشابه
Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives.
UNLABELLED Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some ...
متن کاملProphylactic HPV vaccination: past, present, and future - CORRIGENDUM.
1. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection 2016; 144: 449–468. doi:10.1017/S0950268815002198. Published online: 2 October 2015. Fig. 1. A comparison of vaccine efficacy against targeted HPV type-related (purple bars) and all cervical precancer (CIN2, CIN3, or AIS) (orange bars) by 2vHPV [27], and 4vHPV [28], for the HPV-naive popula...
متن کاملQuadrivalent human papillomavirus vaccine.
The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldwide annually. Infection also causes precancerous lesions and genital warts. HPV types 16 and 18 cause approximately 70% of HPV-related cancers, and HPV types 6 and 11 cause approximately 90% of cases of genital warts. A quadrivalent vaccine for HPV t...
متن کاملProphylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
BACKGROUND A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with >...
متن کاملImmune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.
An AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine has demonstrated excellent efficacy for up to 6.4 years in preventing related persistent infections and cervical precancerous lesions in both Phase II and Phase III clinical trials. The immune responses induced by HPV vaccination are different to those after natural infection. The virus has learned to largely evade our immune system th...
متن کامل